S&P 500
5.048,42 -23,21 (-0,46%) Nasdaq
15.611,76 -100,99 (-0,64%) NIKKEI 225
37.806,77 +178,29 (+0,47%) Dólar/Euro
1,0726 -0,0007 (-0,06%) Petróleo Brent
89,30 +0,29 (+0,33%) Bitcoin EUR
60.096,32 +201,45 (+0,34%)
Aquestive Therapeutics, Inc. (AQST)
Después del cierre:
Aquestive Therapeutics, Inc.
30 Technology Drive
Warren, NJ 07059
United States
(908) 941-1900
https://www.aquestive.com
Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 135
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Daniel Barber | CEO, President & Director | 925,35k | N/A | 1976 |
| Mr. Alexander Mark Schobel | Chief Innovation & Technology Officer | 672,69k | N/A | 1959 |
| Ms. Lori J. Braender BSBA, Esq., J.D. | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 678,76k | N/A | 1956 |
| Mr. A. Ernest Toth Jr. | Chief Financial Officer | 679,9k | N/A | 1959 |
| Ms. Cassie Jung | Senior Vice President of Operations | N/A | N/A | 1979 |
| Mr. Peter E. Boyd | Senior Vice President of IT, HR & Communications | N/A | N/A | 1966 |
| Dr. Gary H. Slatko M.D., MBA | Chief Medical Officer | N/A | N/A | 1958 |
| Dr. Stephen Wargacki | Senior VP of Research & Development | N/A | N/A | 1978 |
| Dr. Carl N. Kraus M.D. | Chief Medical Officer | N/A | N/A | 1970 |
| Mr. Robert Charles Arnold | VP of Finance, Controller & Assistant Secretary | N/A | N/A | N/A |
Descripción
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Gobierno corporativo
El ISS Governance QualityScore de Aquestive Therapeutics, Inc., a día 1 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 9; Tablero: 6; Derechos de los accionistas: 8; Compensación: 7.
